The G-CSF increase was significantly lower in the treated groups compared to the BD group: Coversin group 10,224 pg/mL (328-17166) (p < 0.0001), anti-CD14 group 1412 pg/mL (671–2152) (p < 0.0001) and the dual treatment group 2855 pg/mL (867–4843) (p < 0.0001) (Fig. 3C). The gene discussed is CD14; the disease is Behcet disease.